Menu
Not yet recruiting NCT07653464

Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity

Early Phase I Interventional Obesity (BMI>30) Insulin Resistance

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: human insulin.
Who it may be relevant to
Registry conditions: Obesity (BMI>30), Insulin Resistance. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.

Interventions

  • Drug human insulin
    Participants will be administered human insulin (160 IU) using an intra-nasal device.

Primary outcome measures

  • Amount of muscle sympathetic nerve activity (MSNA) [Time frame: Change from baseline at minute 30]
  • Amount of cerebral blood flow [Time frame: Change from baseline at minute 30]
  • Amount of leg blood flow [Time frame: Change from baseline at minute 30]

Eligibility criteria

Inclusion criteria

  • 18 to 65 years of age

Individuals with obesity and comorbid IR

  • BMI 30-45 kg/m2
  • Waist circumference ≥102 cm (men) or ≥88 cm (women)
  • HOMA-IR ≥2.5

Healthy normal weight adults

  • BMI 18-25 kg/m2
  • Waist circumference <94 cm (men) and <80 cm (women)
  • HOMA-IR <2

Exclusion criteria

  • Pregnancy, breastfeeding
  • Unable to provide consent
  • Diabetes or polycystic ovarian syndrome
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
  • Nerve/neurologic disease
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Current smoking, tobacco, nicotine use
  • Use of pharmacological therapy for weight loss
  • Body weight change >10% within the last 6 months
  • Adherence to >150 min/week of moderate-to-vigorous physical activity/exercise
  • Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months
  • Claustrophobia
  • Non-MRI compatible metal implants

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Missouri — Columbia

Identifiers

NCT: NCT07653464 · 2134707

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗